EGFR and non-small cell lung carcinoma: A subset of patients who do not harbor EGFR mutations could benefit from EGFR-TKIs treatment and a pooled analysis by Lindeman et al. showed an 11% ORR of EGFR-TKIs in patients with EGFR-wt NSCLC assessed by various detection methods [28].